Recent Updates on Atopic Dermatitis Systemic Therapies: Biologics, JAK Inhibitors, Safety, and Emerging Treatments

Conclusions

• For most patients with moderate-to-severe atopic dermatitis, systemic treatment should be individualized through shared decision-making rather than by a rigid first-line hierarchy.
• Biologics remain the most common starting systemic therapy because they are generally safe, effective, and often require no routine laboratory monitoring.
• Phototherapy can be a reasonable alternative for selected patients, but it usually produces only about a 50% improvement over months and is less convenient than systemic drugs.
• Dupilumab has the strongest overall safety and breadth of use among biologics, including use in very young children and patients with multiple type 2 comorbidities.
• Pregnancy data presented for dupilumab and biologics more broadly were reassuring, with no clear signal for increased congenital anomalies or adverse pregnancy outcomes in the available observational studies.
• Tralokinumab and lebrikizumab appear effective and durable over time, and some patients who fail dupilumab can improve after switching to these IL-13 biologics.
• Nemolizumab provides very rapid itch relief and has reassuring longer-term safety, though its skin efficacy may be somewhat less robust than some other biologics.
• Facial dermatitis and conjunctivitis on biologics do not automatically require avoiding dupilumab or tralokinumab, since many patients actually improve with continued treatment plus targeted topical management.
• Arthralgias and inflammatory arthritis can occur during dupilumab therapy and may also occur, though perhaps less often, with IL-13 blockade, so new joint symptoms warrant attention and sometimes a switch in therapy.
• New psoriasiform or other atypical rashes during biologic or JAK treatment should prompt reassessment, with special caution to not miss cutaneous T-cell lymphoma in severe or atypical disease.
• The best available cohort data did not show an increased CTCL risk from dupilumab itself, suggesting that underlying severe atopic dermatitis is a major confounder.
• JAK inhibitors, especially at higher doses, tend to produce faster and deeper skin and itch responses than dupilumab and are valuable for biologic-refractory disease or JAK-responsive comorbidities.
• Long-term JAK safety data were overall reassuring for serious outcomes, though herpes zoster, acne, nausea, and some infection risks remain important counseling points and older patients deserve extra caution.
• Dose escalation and de-escalation strategies can be used with both biologics and JAK inhibitors, but some patients need higher or more frequent dosing to maintain control.
• A gene-expression test may help later therapy selection, but its incremental value is modest because the general pattern of JAKs outperforming biologics is already known in many patients.
• Future directions include OX40-pathway therapies and other emerging agents, but safety signals such as Kaposi’s sarcoma can halt development.
• Overall, the presentation supports treating the right patient with the right systemic agent, with therapy changes driven by efficacy, adverse effects, comorbidities, and patient preferences rather than by one universally preferred drug.